The effects of chelators on zinc levels in patients with thalassemia major

Journal of Trace Elements in Medicine and Biology

Volumn 27, Issue 2, 2013, Pages 109-111

  Erdoĝan, Elvan ^a   Canatan, Duran ^a   Örmeci, Ahmet Rifat ^a   Vural, Hüseyin ^a   Aylak, Firdevs ^a  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Chelators; Thalassemia; Zinc deficiency

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ZINC;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR; URINALYSIS; ZINC BLOOD LEVEL; ZINC DEFICIENCY; ZINC URINE LEVEL;

ADOLESCENT; BENZOATES; BETA-THALASSEMIA; DEFEROXAMINE; DEMOGRAPHY; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; PYRIDONES; TRIAZOLES; YOUNG ADULT; ZINC;

EID: 84875098366     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2012.10.002     Document Type: Article

References (20)

1. Weatherall D.J., Clegg J.B. Management and prognosis in the thalassemia syndromes 2001, Blackwell Scientific, Oxford, UK, p. 630-85. 4th ed.
2. Ceci A., Mangiarini L., Felisi M., Bartoloni F., Ciancio A., Capra M., et al. The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients. Anemia 2011, 2011:435683.
3. Hoffbrand A.V., Taher A., Cappellini M.D. How I treat transfusional iron overload. Blood 2012, [Epub ahead of print].
4. Prasad A.S. Discovery of human zinc deficiency and experimental human model. Am J Clin Nutr 1991, 53:403-412.
5. Arcasoy A., Cavdar A. Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia. Acta Haematol 1975, 53:341-344.
6. Doĝru ü., Arcasoy A., çavdar A. Zinc levels of plasma, erythrocyte, hair and urine in homozygote beta thalassemia. Acta Haemat 1979, 62:41-44.
7. Arcasoy A., Canatan D., Sinav B., Kutlay L., Oguz N., Sen M. Serum zinc levels and zinc binding capacity in thalassemia. J Trace Elem Med Biol 2001, 15:85-87.
8. Mehdizadeh M., Zamani G., Tabatabaee S. Zinc Status in patients with major beta-thalassemia. Pediatr Hematol Oncol 2008, 25:49-54.
9. Uysal Z., Akar N., Kemahli S., Dincer N., Arcasoy A. Desferrioxamine and urinary zinc excretion in beta-thalassemia major. Pediatr Hematol Oncol 1993, 10(3):257-260.
10. Aydinok Y., Coker C., Kavakli K., Polat A., Nisli G., Cetiner N., et al. Urinary zinc excretion and zinc status of patients with beta-thalassemia major. Biol Trace Elem Res 1999, 70(November (2)):165-172.
11. Cohen A.R., Galanello R., Piga A. Safety profile of the oral chelator deferiprone: a multi-centre study. Br J Hematol 2000, 108:305-312.
12. Galanello R., Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009, 122(2-3):155-164.
13. Bartakke S., Bavdekar S.B., Kondurkar P., Muranjan M.N., Manglani M.V., Sharma R. Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major. Indian Pediatr 2005, 42:150-154.
14. Claster S., Wood J.C., Noetzli L., Carson S.M., Hofstra T.C., Khanna R., et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol 2009, 84(June (6)):344-348.
15. Anastassopoulou J., Anifantakis B., Anifantakis Z.A., Dovas A., Theophanides T. The role of free radical reactions with haemoglobin and thalassaemia. J Inorg Biochem 2000, 79(April (1-4)):327-329.
16. Galanello R., Agus A., Campus S., Danjou F., Giardina P.J., Grady R.W. Combined iron chelation therapy. Ann N Y Acad Sci 2010, August, 1202:79-86.
17. Lai M.E., Grady R.W., Vacquer S., Pepe A., Carta M.P., Bina P., et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis 2010, 45(August (2)):136-139.
18. Kattamis A., Ladis V., Berdousi H., Kelekis N.L., Alexopoulou E., Papasotiriou I., et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. Blood Cells Mol Dis 2006, 36:21-25.
19. Cappellini M.D., Bejaoui M., Agaoglu L., Canatan D., Capra M., Cohen A., et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011, 118:884-893.
20. Farmaki K., Tzoumari I., Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011, 47(June (1)):33-40.